Insulin replacement therapy is integral to the management of type 1 diabetes, which is characterised by absolute insulin deficiency. Optimal glycaemic control, as assessed by glycated haemoglobin, and avoidance of hyper-and hypoglycaemic excursions have been shown to prevent diabetes-related complications. Insulin pump use has increased considerably over the past decade with beneficial effects on glycaemic control, quality of life and treatment satisfaction. The advent and progress of ambulatory glucose sensor technology has enabled continuous glucose monitoring based on real-time glucose levels to be integrated with insulin therapy. Low glucose and predictive low glucose suspend systems are currently used in clinical practice to mitigate against hypoglycaemia, and provide the first step towards feedback glucose control. The more advanced technology approach, an artificial pancreas or a closed-loop system, gradually increases and decreases insulin delivery in a glucose-responsive fashion to mitigate against hyper-and hypoglycaemia. Randomised outpatient clinical trials over the past 5 years have demonstrated the feasibility, safety and efficacy of the approach, and the recent FDA approval of the first single hormone closed-loop system establishes a new standard of care for people with type 1 diabetes.
Introduction
Type 1 diabetes represents 5-10% of diabetes cases worldwide. The prevalence over the past 20 years however has doubled, increasing the burden of the condition for individuals and society (Atkinson et al., 2014) . The cause of type 1 diabetes is an absolute insulin deficiency due to autoimmune destruction of beta-cells (Atkinson et al., 2014) . Thus, the mainstay of type 1 diabetes treatment is insulin replacement therapy with the goal of achieving near normoglycaemia to reduce the risk of diabetes-related micro-and macrovascular complications (Nathan et al., 1993) . However, tight glycaemic control increases the risk of hypoglycaemia with potentially severe acute and long-term sequelae (Frier, 2014) .
Successful management of type 1 diabetes entails frequent glucose monitoring and insulin dose adjustment. Conventional insulin therapy management is based on the administration of prandial insulin at mealtimes, and basal insulin to control glycaemia during fasting and between meals (Fig. 1) . The introduction of insulin pump therapy and insulin analogues into clinical practice has allowed modern insulin therapy to become more flexible to suit individuals' lifestyle. Still, the lack of a physiological-like feedback for insulin delivery prevents recommended therapy targets to be achieved as daily insulin requirements can vary widely due to complex interactions between the nutritional intake, physical activity and hormonal milieu (Ruan et al., 2016) .
Advances in diabetes technology over the past decades have led to the development of continuous glucose monitoring (CGM) which measure the real-time interstitial glucose concentration (Rodbard, 2016) . Conventional CGM sensors are externally worn. Recently however, an implantable CGM with sensor life of up to six months has been developed [http://www.senseonics.com/investor-relations/newsreleases/2017/09-12-2017-213230489]. Coupling of CGM to insulin delivery via a control algorithm, known as a closed-loop system or the artificial pancreas, has enabled device-centred automated glucose-responsive insulin delivery to be progressed . This allows modulation of insulin-delivery to address the constantly changing insulin requirements and to reduce the burden of daily self-management.
In this review article, we outline the present landscape of insulin pump therapy and introduce the concept of glucose-responsive automated insulin delivery or closed-loop systems. Current limitations and future developments of closed-loop therapy are also discussed.
Insulin pump therapy
Continuous subcutaneous insulin infusion, commonly known as "insulin pump therapy", was introduced in the 1970s (Pickup et al., 1978) . It is increasingly used in clinical practice as an alternative to multiple daily injection (MDI) therapy. The increased uptake of insulin pump therapy is in part due to the Diabetes Control and Complications Trial (DCCT, 1993) , which showed significant decrease in microvascular disease risk with intensive insulin therapy (Nathan et al., 1993) . The evidence from clinical studies evaluating the safety, clinical and cost effectiveness of insulin pump therapy has been published (Pozzilli et al., 2015) . Guidelines and recommendation for insulin pump therapy are available for health care professionals involved in the management of people with type 1 diabetes (Peters et al., 2016) .
Insulin pump features and functionalities
The advantage of insulin pumps over injection therapy is the ability to set different pre-programmed basal rates of insulin delivery throughout the day to match the individual's varying diurnal insulin needs (Pickup, 2012) . Moreover, insulin pumps allow for meal insulin to be delivered using different bolus profiles, to suit meals of different macronutrient composition and absorption; insulin boluses can either be delivered immediately (known as standard, immediate or step bolus), or over several hours (square or extended wave bolus), or as a combination of the two (dual wave bolus). Modern insulin pumps have integrated bolus calculators used by the user to determine the appropriate insulin bolus dose, by inputting pre-meal blood glucose levels and estimated carbohydrate intake. The bolus calculator provides the recommended bolus dose by taking into account the pre-programmed target glucose, insulin sensitivity, insulin to carbohydrate ratio and amount of active insulin remaining (known as insulin on board) (Zisser et al., 2008) . Most insulin pump devices have alarms to alert the user in case of an occlusion or other technical malfunctions to increase safety of the approach. Glucose, insulin and user specific data, such as bolusing behaviour, can be downloaded and used by users and healthcare professionals to identify areas requiring further attention to optimise glycaemic control.
Conventional insulin pump devices deliver insulin via plastic tubing, and teflon or steel cannula changed every 2-3 days and inserted subcutaneously. Disadvantages include the aesthetic concerns and the risk of kinking or disconnection of the tubing. Tubingless or patch pumps have an integrated short infusion cannula and are attached directly to the body with an adhesive patch. However, the remote controller might get lost or forgotten disabling bolus application.
The use of insulin pumps can be augmented by the use of CGM. The approach is known as sensor-augmented pump therapy (SAP). Interstitial glucose is measured every 1-5 min, and glucose values are either sent directly to the pump, or to separate hand-held receiver. User input is needed to manually adjust insulin pump delivery in conventional SAP systems based on CGM or capillary glucose measurements.
Clinical evidence in support of insulin pump therapy
A meta-analysis of relatively short-term randomised controlled trials showed a mean reduction in glycated haemoglobin (HbA1c) of 0.3-0.6% (3-6 mmol/mol) (Pickup and Sutton, 2008; Misso et al., 2010) during insulin pump therapy compared to MDI. This was accompanied by a 20% reduction in total daily insulin dose. Pooled data from randomised controlled and observational studies, in which users switched from MDI to insulin pump therapy, showed that the greatest improvement in HbA1c occurred in those with the highest baseline HbA1c (Pickup and Sutton, 2008) ; those with baseline HbA1c of 9% (75 mmol/mol) on MDI showed an HbA1c reduction of approximately 1.5% (16 mmol/mol) when switching to insulin pump therapy whilst the reduction was less than 0.5% (5 mmol/mol) in those with baseline HbA1c of 7.5% (58 mmol/mol).
A further reduction in HbA1c was observed when conventional insulin pump users were switched to SAP with the degree of HbA1c improvement again dependent on baseline HbA1c (Pickup et al., 2011) . Regular glucose sensor use was also a determinant factor. An observational study related to long-term outcomes on insulin pump therapy demonstrated sustainability of glycaemic control over prolonged use of insulin pump therapy (Beato-Víbora et al., 2015) .
The majority of clinical studies have shown that the burden and risk of hypoglycaemia are ameliorated by insulin pump therapy compared to MDI. A meta-analysis of studies evaluating those at increased hypoglycaemia risk showed overall a 75% reduction in severe hypoglycaemia events requiring third party assistance, when users were switched from MDI to insulin pump therapy (Pickup and Sutton, 2008) , and the relative risk reduction was at least 10-fold in those with the highest baseline risk. Hypoglycaemia reduction was observed to a lesser extent in children, likely due to the shorter duration of diabetes and a lower baseline frequency of severe hypoglycaemia (Pickup and Sutton, 2008) . Hypoglycaemia occurrence has been shown to be related to increased glucose variability (Kilpatrick et al., 2007) . Insulin pump therapy has been shown to reduce within-day and between-day glycaemic variability, which may in part contribute towards ameliorating the risk of hypoglycaemia.
A notable difference between older studies such as the Diabetes Fig. 1 . The concept of basal bolus insulin therapy. Basal insulin provides background insulin for periods between meals and overnight. Bolus insulin targets meal-related glucose excursions.
Control and Complications Trial and more recent studies which compared MDI with insulin pump therapy is the wider use of insulin analogues during the latter. As such, reported outcomes from these studies and meta-analysis may not be directly comparable and need to be interpreted with caution (Pickup and Sutton, 2008; Misso et al., 2010; Weissberg-Benchell et al., 2003) . In addition, those with hypoglycaemia-unawareness were often excluded and therefore findings may not be generalizable to those with significant burden of hypoglycaemia (Pickup, 2012) . The incremental benefits of insulin pump therapy over MDI using novel long-acting insulin analogues which have shown less pharmacodynamics variability, in conjunction with state-of-the-art functional insulin therapy education programmes, remain unclear.
Improvements in the quality of life and treatment satisfaction amongst insulin pump users however have been consistently shown (DeVries et al., 2002) . A recent study evaluated the glycaemic benefits of insulin pump therapy in adults with type 1 diabetes on MDI regime already using CGM. Participants used the G4 sensor (Dexcom, San Diego, CA, USA) and the Insulet OmniPod insulin pump (Insulet, Billerica, MA, USA) during the intervention period. Efficacy endpoints were assessed over a period of 28 weeks and showed a mean reduction in sensor glucose by 0.8 mmo/l (14 mg/dl), and a 6% or 83 min per day increase in time spent with sensor glucose in target range (3.9-10.0 mmol/l [70-180 mg/dl]), when insulin pump-CGM users were compared to MDI-CGM. This came at the expense of increased time spent hypoglycaemic (Beck et al., 2017) . HbA1c levels remained unchanged following transition from MDI to insulin pump therapy.
Continuous intraperitoneal insulin delivery
Continuous intraperitoneal insulin infusion (CIPII) may confer some advantages due to the more favourable pharmacokinetic profile compared to subcutaneous insulin delivery, with faster absorption rate and restoration of physiological portal-peripheral gradient (Schade et al., 1981) . This led to the development of implantable insulin pumps which began in the 1970s. Implantable pumps were initially manufactured by several companies such as Infusaid Inc. (Norwood, MA, USA), MiniMed Inc. (Sylmar, CA, USA) and Siemens-Elema (Solna, Sweden). MiniMed Inc. has since merged with Medtronic, and the Minimed 2007 remains the only commercially implantable pump available at present. It is approved for clinical use in Europe, however, it is limited to Medtroniccertified centres in Netherlands, Belgium, Sweden and France.
Despite their theoretical advantages, regulatory approval and implementation of IPI in clinical practice have been limited, due to concerns related to long-term safety, maintenance, costs and regular need of specialist input (Bally et al., 2016) . Reports and studies evaluating implantable insulin pump use with surfactant-stabilized U-400 insulin formation and clinical feasibility of IPI have been published, albeit in a small number of users and centres (Logtenberg et al., 2009; van Dijk et al. 2015; Schaepelynck et al., 2011) .
The Accu-Chek Diaport system (Roche Diabetes), which involves the use of percutaneous access, is a less invasive approach of CIPII (Liebl and Frei, 2003) . It composes of a catheter which is inserted in the peritoneal space and fixed to a surgically implanted metallic body attached to the skin. The outer port (located externally approximately 2-3 mm from the skin), is connected to an external insulin pump device (Accu-Chek Spirit Combo pump, Roche Diagnostics, Mannheim, Germany). Infused insulin through the Diaport system is a regular U-100 insulin (Insuman Infusat, Sanofi, Paris, France) as rapid-acting insulin analogues have not been approved for intraperitoneal delivery. In a multi-centre cross-over design study, sixty participants with type 1 diabetes were randomised to intraperitoneal insulin infusion using DiaPort system with regular insulin (Insuman U-100), or subcutaneous insulin pump therapy with lispro for 12 months (Liebl et al., 2009 ). The primary endpoint, incidence of hypoglycaemia, was comparable between both treatments groups (p = .91), whereas the number of severe hypoglycaemia events was halved during the DiaPort use (34.8 vs. 86.1 events/100 patient years, p = .013). The number of participant dropouts however was relatively high (24/30 and 12/30 in the DiaPort and subcutaneous insulin pump group, respectively), which the authors attributed to participants' fear of potential complications of intraperitoneal delivery, and reluctance to use it. The commonest adverse event is infection around the percutaneous port. The second generation DiaPort was introduced in 2011, re-designed with a Dacron cuff around the percutaneous access port to provide a barrier to infection and better stabilization of the port at the implantation site, which could potentially minimise the incidence of serious or persistent infections. Nonrandomised single-arm studies with relatively small number of participants have been performed (i.e. ClinicalTrials.gov NCT01483352); results are yet to be published.
Limitations of insulin pump therapy
Modern insulin pumps are provided with alarms for catheter occlusion, pump mechanism failures and low battery. However, if not vigilant or well-trained, pump users could be exposed to clinically significant adverse events due to specific limitations of insulin pump therapy. In contrast to basal bolus MDI regime, the lack of long-acting insulin puts insulin pump users at an increased risk of diabetic ketoacidosis due to insulin deficiency in the event of prolonged catheter displacement, occlusion or kinking. In a cross-sectional survey of pump users, nearly half reported some form of insulin delivery problems, either due to infusion set or pump device issues (Pickup et al., 2014) . The use of the infusion set longer than 3 days was also associated with insulin delivery and absorption issues. A comparison between steel and teflon catheters found a 15% rate of initial infusion set failure with the latter, due to the catheters kinking on insertion (Patel et al., 2014) . This highlights the importance of user and health-care provider adherence to appropriate pump care and guidelines such as sick day rules and set change intervals, to mitigate against common hazards of pump therapy. Post marketing surveillance programmes of pump therapy are needed to ensure safety standards are met and to improve the reliability of pump components by manufacturers. Concerns of potentially higher risk of DKA during insulin pump therapy was recently challenged by a systematic review which reported lower prevalence of DKA in adult insulin pump users compared to MDI (Fazeli Farsani et al., 2017) . Likewise, a recent population-based cohort study involving 30,579 individuals aged between 1 and 20 years reported lower risk of ketoacidosis in pump users compared to insulin injection therapy (Karges et al., 2017) . This however does not abdicate the need for continuous vigilance and education of insulin pump users.
Health economic analyses have shown that the cost of insulin pump therapy is notably higher than MDI. The annualised cost of pump therapy in the UK, which includes device and consumables expenses over a warranty period, is approximately £1700 greater compared to MDI. In addition, the educational input for pump users is difficult to quantify. Overall, the cost-effectiveness was shown to be in favour of insulin pump therapy relative to MDI, due to an projected 1.2% (2 mmol/mol) HbA1c reduction (Cummins et al., 2010) . Others have shown pump therapy to be cost-effective when health economic model such as the Centre for Outcomes Research (CORE), which accounts for the quality of life in addition to HbA1c, was used (Roze et al., 2015) . It is important to note that these models currently do not evaluate the burden of hypoglycaemia on the individual and society, such as loss of productivity at work or school, and mental health issues associated with fear of hypoglycaemia.
Insulin pump therapy with threshold suspend features
SAP has been shown to lead to a significant improvement in diabetes management allowing the user to set personalised alarms. However, users do not always take the appropriate actions following an alert. To reduce the risk of hypoglycaemia, approaches that automatically suspend insulin delivery have been developed and tested in randomised clinical trials (Table 1) .
Low glucose suspension of insulin delivery
Automatic cessation of insulin delivery at a pre-set threshold sensor glucose value is referred to as low glucose suspend (LGS). A LGS event initiates up to 2 h suspended insulin delivery; insulin delivery can resumed earlier by the user. The Paradigm VEO system (Medtronic MiniMed, Inc, Northridge, CA, USA) was the first pump with built-in LGS feature and introduced in Europe in 2009. The use of LGS over an extended period of time in hypoglycaemia prone individuals reduced the risk and frequency of nocturnal hypoglycaemia without increasing HbA1c (Bergenstal et al., 2013; Ly et al., 2013) . In 2013, the ASPIRE InHome Study Group evaluated the effect of SAP with LGS (Bergenstal et al., 2013) compared to SAP alone, on nocturnal hypoglycaemia and HbA1c levels in participants at increased risk of nocturnal hypoglycaemia (experienced ≥2 nocturnal hypoglycaemic events during the 2-week run-in phase). Mean AUC for nocturnal hypoglycaemic events was significantly decreased by 32% in the LGS group after 3 months compared to control. Time spent hypoglycaemic was also significantly lower in LGS compared to control. Others have shown that the initial excess cost of LGS therapy is balanced by avoidance of hypoglycaemiarelated healthcare expenditures (Ly et al., 2014; Roze et al., 2016) .
Predictive low glucose suspension of insulin delivery
Algorithms that suspend insulin delivery before a threshold low glucose value is reached have been developed and are referred to as predictive low glucose suspend (PLGS) systems (i.e. Medtronic MiniMed 640G pump) aiming to reduce further the burden of hypoglycaemia. Briefly, the 640G algorithm suspends insulin delivery when the glucose level is predicted to drop to a level equal to or lower than a pre-set threshold within 30min. Once the predicted glucose is safely above the threshold or after 2 h, insulin delivery is resumed (Fig. 2) . Randomised clinical trials with PLGS have reported reduced nocturnal hypoglycaemia burden compared to SAP. PLGS decreased the burden of hypoglycaemia as measured by the median hypoglycaemia area under the curve by 81%, and hypoglycaemia lasting > 2 h was reduced by 74% in a 42-night randomised trial involving adolescents and adults with type 1 diabetes (Maahs et al., 2014) . A recent analysis of PLGS use in clinical practice showed reduction of hypo-and hyperglycaemic events during both night and daytime (Zhong et al., 2016) . Table 1 summarises randomised controlled trials evaluating efficacy of LGS and PLGS in type 1 diabetes.
Closed-loop insulin delivery
Closed-loop systems or the artificial pancreas are more advanced than LGS and PLGS system and autonomously and gradually increase and decrease subcutaneous insulin delivery according to real-time sensor glucose levels. Such a glucose-responsive insulin technology aims to mimic physiology of the pancreatic beta cell by providing insulin delivery commensurate with acute individual metabolic needs. Closed-loop insulin delivery has the potential to reduce the burden of diabetes self-management.
4.1. Closed-loop system components 4.1.1. Overview
Closed-loop systems consist of a glucose sensor, an insulin pump and a control algorithm which is either embedded in the pump or residing in a separate device, e.g. a smartphone (Fig. 3) . These components communicate wirelessly. The key component of a closed-loop system is the control algorithm, which directs insulin delivery according to realtime glucose levels while accounting for inter-and intra-subject Table 1 Randomised controlled home studies of threshold suspend (low glucose and predictive low glucose). Reference LGS Conventional pump therapy Day-and-night, 6 months Combined incidence of severe (seizure or coma) and moderate hypoglycaemia (third party assistance). 9.5 vs. 34.2 events/100 patient months (incidence ratio 3.6, p < 0.001), LGS vs. conventional pump therapy LGS, Low Glucose Suspend; PLGS, Predictive Low Glucose Suspend; SAP, Sensor-Augmented Pump Therapy. variability, inherent sensor and insulin delivery errors as well as kinetic delays. Various algorithms have been developed and the two most commonly used are the proportional-integral-derivative control and the model-predictive control approach (Doyle et al., 2014) .
Proportional-integral-derivative control
The proportional-integral-derivative algorithms adjust insulin delivery by considering deviations from a target glucose level (proportional component), the area under the curve between the measured and target glucose level (integral component), and the rate of change in the measured glucose levels (derivative component).
Model predictive control
The model predictive control algorithms employ a mathematical model of glucose regulation to predict glucose excursions. Insulin delivery is calculated by minimizing the difference between model-predicted glucose-concentrations and the target glucose levels over a prespecified prediction time horizon.
Other clinically evaluated control approaches include the fuzzy logic approach which modulates insulin delivery on the basis of approximate rules to express the empirical knowledge of diabetes practitioners (Nimri et al., 2014aa) . Most control algorithms include safety modules to constrain insulin delivery, limiting the amount of insulin on board or the maximum rate of insulin delivery, or suspending insulin delivery when glucose levels are low or decreasing.
Types of closed-loop systems

Overview
The two main approaches are (i) hybrid closed-loop systems that require for optimal performance manual input through user-initiated insulin boluses at meal times and (ii) fully closed-loop systems which operate autonomously without the need for user-initiated prandial insulin boluses. The performance of the latter is limited by the delayed action profile of subcutaneous insulin delivery (Weinzimer et al., 2008) and is currently not pursued commercially. The hybrid closed-loop system overcomes delays through bolus delivery and announcement to the control algorithm of meals (Fig. 4) . The hybrid systems are the focus of current translational research.
Closed-loop systems using either single-hormone (insulin only) or dual-hormone (insulin and glucagon) have been studied.
Co-delivery of glucagon
Glucagon counteracts insulin action through mobilization of the endogenous glucose production from the liver (Haidar et al., 2016a) . The aim of glucagon delivery in closed-loop systems is either to alleviate solely the risk of hypoglycaemia, or to enable insulin to be delivered more aggressively and counteract insulin overdelivery (Taleb et al., 2017) . The control algorithm of the former is similar to that of a single hormone approach. Glucagon is given intermittently as mini boluses by a separate pump chamber, with daily doses ranging up to 1 mg/day (Taleb et al., 2017) . Currently available glucagon formulations, such as GlucaGen® (Novo Nordisk, Bagsvaerd, Denmark), consist of lyophilized powder that requires daily reconstitution due to protein aggregation and degradation (Caputo et al., 2013) , and as such addition of glucagon to a closed-loop system could therefore impose further burden and complexity to the user.
Co-delivery of incretin-based therapies
Apart from glucagon, use of other hormone-based therapies in combination with closed-loop insulin delivery have been proposed. The adjunctive use of amylin analogues and incretin-based therapies may attenuate peak meal-related glucose appearance and improve postprandial glycaemia by delaying gastric emptying and suppressing meal- induced glucagon response (Hinshaw et al., 2013) .
Pramlintide is a synthetic analogue of amylin and has been shown to improve postprandial-prandial glucose control when injected pre-meal during single-hormone closed-loop operation (Weinzimer et al., 2012) . Combining single-hormone closed-loop insulin-delivery with a GLP-1 receptor agonist (liraglutide) was shown to mitigate against meal-induced glycaemic excursions whilst having an insulin-sparing effect, when compared to adjunct use of amylin (Sherr et al., 2016) . The addition of DPP-4 inhibitor to single-hormone closed-loop improved postprandial glycaemic control, compared to closed-loop alone (Underland et al., 2017) . Despite its benefit however, concerns regarding gastrointestinal side-effects remain.
From prototypes to commercial hybrid closed-loop pump
Several closed-loop prototypes have been developed by different academic and commercial entities. Academic prototypes host the control algorithm on a separate device, such as a smartphone, to ease development and regulatory issues (Fig. 5A) . In September 2016, the US Food and Drug Regulatory Authority approved the first commercial closed-loop system (MiniMed® 670G pump, Medtronic, Northridge, CA) for use in clinical practice, based on a non-randomised safety-focused pivotal clinical trial (FDA News Release, 2016) . 670 G pump is a singlehormone hybrid closed-loop system, with the control algorithm integrated in the pump (Fig. 5B) . It is expected that 670G pump will be available in Europe in 2018/2019. Other groups and manufacturers are also currently developing closed-loop systems for commercialisation. Bigfoot Smartloop™ system and the Omnipod Artificial Pancreas™ system are both undergoing pilot clinical evaluations (NCT02849288 and NCT02897557, respectively). Closed-loop systems developed by Type Zero Inc (http://typezero.com/) and the DIABELOOP consortium are undergoing multicentre pivotal testing (NCT02985866 and NCT02987556, respectively). Commercialisation of a bi-hormonal closed-loop system in Europe is planned (Trevitt et al., 2016 ). An integrated dual-hormone system (ILet) is currently being tested in a feasibility trial in the US (NCT02701257). Do-it-yourself closed-loop systems are being developed and used by the sizable open-source community (https://openaps.org).
Clinical evidence
Over the past decade, clinical studies have progressed from controlled research facility and supervised transitional settings Phillip et al., 2013 ) to free-living home studies (Thabit et al., 2015; Kropff et al., 2015) . Table 2 summarises the findings from key single-and dual-hormone randomised controlled free-living closed-loop studies. The longest randomised study by Thabit et al contrasted day-and-night hybrid closed-loop use with sensor-augmented pump therapy over three months and showed improvements in time in target glucose range, HbA1c and hypoglycaemia (Thabit et al., 2015) .
A meta-analysis including 585 adult and paediatric participants from 24 randomised controlled closed-loop studies showed that closedloop increased time spent in sensor glucose target range (3.9-10.0 mmol/l) by approximately 13 percentage points (p < .0001) (Weisman et al., 2017) . A comparison of time spent hypoglycaemic Fig. 4 . Glucose levels and insulin delivery profiles during a hybrid single hormone closed-loop study (Bally et al., 2017) The bold red line shows the continuous subcutaneous glucose trace. Control algorithm-directed insulin infusion rates during closed-loop are denoted by the thick blue line. Vertical arrows indicate meals and snacks (orange arrows) and blue vertical lines illustrate insulin boluses administered by the user at meal times. Horizontal dashed red lines indicate the target glucose range from 3.9 to 10 mmol/l. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
Table 2
Randomised controlled home studies of single-hormone and dual-hormone closed-loop systems.
Reference Tauschmann et al., El-Khatib et al., LGS, Low Glucose Suspend; PLGS, Predictive Low Glucose Suspend; PHHM, Predictive Hyperglycaemia and Hypoglycaemia Minimization; SAP, Sensor-Augmented Pump Therapy, CL, Closed-Loop.
(sensor glucose < 3.9 mmol/l) from 463 participants showed that closed-loop reduced time spent hypoglycaemic by 2.5 percentage points or 35 min per day (p < .0001).
The incremental benefits of a single-hormone closed-loop system were reported in a randomised crossover trial by Bally et al involving type 1 diabetes adults with tight glycaemic control (HbA1c < 7.5% [58 mmol/mol]). A hybrid closed-loop use in adults with baseline HbA1c of 6.9% (52 mmol/mol) showed improvement in glucose control whilst reducing the burden of hypoglycaemia (Bally et al., 2017) . Improvements in time in target and lower mean glucose were also shown using hybrid closed-loop in pregnant women with type 1 diabetes compared to sensor-augmented pump therapy (Stewart et al., 2016) without increasing the risk of hypoglycaemia.
The largest non-randomised closed-loop study to date by Bergenstal et al involved 124 participants (30 adolescents aged 14-21 years and 94 adults aged 22-75 years) over 3 months with the primary aim being safety rather than efficacy of closed-loop use (Bergenstal et al., 2016) . In the longest closed-loop study to date, also non-randomised, day-andnight hybrid closed-loop was used in 14 adults over 6 months with median proportion of time in sensor glucose target range [3.9-10.0 mmol/l (70-180 mg/dl)] of 76% during daytime and 78% during night-time. Closed-loop use declined over time from median values of 87% at the beginning to 70% at the end of the study (Kovatchev et al., 2017) .
The efficacy and safety of a single-hormone fully closed-loop system with intraperitoneal insulin delivery through the DiaPort system was assessed in a non-randomised parallel design 24-h inpatient study by Dassau et al involving 10 adults with type 1 diabetes (Dassau et al., 2017) . Compared to subcutaneous insulin delivery, intraperitoneal insulin delivery with a modified control algorithm led to higher percen- 
Limitations
Although a significant progress has been made, further enhancements could improve closed-loop performance. The delayed absorption of present rapid-acting insulin analogues remains a barrier to optimum closed-loop performance (Home, 2012) and contributes to a less favourable performance during daytime compared to night-time as mealrelated excursions and physical activity induce rapid changes in insulin requirements. As such, the delayed insulin action contributes to the residual risk of hypoglycaemia observed with single-hormone systems in the late post-prandial period and during exercise. Ultrafast insulin analogues with accelerated pharmacokinetics have been developed as a solution to overcome these limitations (Heise et al., 2017) . Another approach to enhance the pharmacokinetic profile of subcutaneous insulin delivery comprises local warming devices which accelerates insulin absorption following bolus delivery (El-Laboudi and Oliver, 2015) .
Although the addition of glucagon may confer additional benefits in terms of hypoglycaemia reduction, it also adds to the complexity, cost, and burden of the system to the user. Safety data on the long-term use of subcutaneous glucagon are lacking. A recent qualitative study assessing the psychosocial impact of dual hormone closed-loop system in adults reported a reduction in diabetes-related distress, especially with respect to hypoglycaemia. However, > 75% of users highlighted the burden of daily glucagon replacement and carrying multiple devices (Weissberg-Benchell et al., 2017) . Device burden is recognised as an important factor potentially limiting the uptake and sustained use of closed-loop systems, thus highlighting the importance of managing user expectations and needs (Iturralde et al., 2017) . Closed-loop users will need to be made aware of the need for associated activities, e.g. the need for sensor calibration, and bolusing for hybrid closed-loop systems, and troubleshooting resilience to resolve, for example, connectivity problems.
Outlook and conclusion
Closed-loop systems are unique through automated glucose-responsive insulin delivery at hyper-and hypoglycaemia. The FDA approval of the single-hormone hybrid closed-loop system has confirmed closed-loop systems as a realistic therapeutic modality for type 1 diabetes.
Strategies to improve closed-loop technology include the use fasteracting insulin formulations (Heise et al., 2017) , local warming devices such as the Insupad (El-Laboudi and Oliver, 2015), alternative insulin delivery routes (Dassau et al., 2017) and adjunctive incretin-based therapies (Weinzimer et al., 2012; Sherr et al., 2016; Renukuntla et al., 2014) . A further progress in glucose sensor technology may increase sensor accuracy, prolong sensor lifetime and facilitate factory calibration (Bolinder et al., 2016) . The Eversense implantable sensor system (Senseonics, Inc., MD, USA), which was recently approved in Europe, allows long-term up to 6 months continuous use of sensor glucose with consistent accuracy throughout its use (Kropff et al., 2017) . The development of stable glucagon formulations (Castle et al., 2016) and dual chamber pumps for insulin and glucagon co-delivery may provide incremental benefits to those with increased hypoglycaemia-burden and risk. Minimising device burden through integration of closed-loop components is likely to enhance user uptake. Cloud-based interface would enable users' data to be uploaded and viewed by their healthcare professionals, thereby facilitating virtual clinic consultations and remote monitoring by parents and guardians. Personalisation of closedloop systems can potentially be achieved by more adaptive algorithms (Doyle et al., 2014) and the use of input signals related to physical activity and exercise such as heart rate, accelerometry (Jacobs et al., 2015) .
Longer studies evaluating biomedical and psychosocial outcomes as well as cost-effectiveness are needed to support reimbursement. The immediate impact on existing structured education programmes is unknown and adjustment may be needed. The rapid progress from the bench to bedside has made closed-loop a realistic treatment option and is expected to lead to better care and quality of life for people with type 1 diabetes.
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